Scancell Holdings Plc Notice of Final Results (1423P)
15 Octubre 2021 - 1:00AM
UK Regulatory
TIDMSCLP
RNS Number : 1423P
Scancell Holdings Plc
15 October 2021
15(th) October 2021
Scancell Holdings plc
("Scancell" or the "Company")
Notice of Final Results
Scancell Holdings plc, (AIM:SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
expects to announce its financial results for the year ended 30
April 2021 on Friday, 29 October 2021.
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr John Chiplin, Executive Chairman
Professor Lindy Durrant, CEO
Panmure Gordon (UK) Limited (Nominated Adviser
and Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Natalie Garland-Collins
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its technology platforms, ImmunoBody(R) ,
Moditope(R) and AvidiMab(TM) , with four products in multiple
cancer indications and development of a vaccine for COVID-19.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
CD4 and CD8 T cells with the ability to identify, target and
eliminate cancer cells. These cancer vaccines have the potential to
be used as monotherapy or in combination with checkpoint inhibitors
and other agents. The Directors believe that this platform has the
potential to enhance tumour destruction, prevent disease recurrence
and extend survival.
DNA vaccine against COVID-19: As research data emerges, it is
becoming increasingly clear that the induction of potent and
activated T cells may play a critical role in the development of
long-term immunity and clearance of virus-infected cells. Initial
research is underway and Scancell anticipates initiating a Phase 1
clinical trial known as COVIDITY during 2021.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). Examples of such
modifications are citrullination, an enzyme-based conversion of
arginine to citrulline, and homocitrullination (or carbamylation),
in which lysine residues are converted to homocitrulline.
Expression of peptides containing these modifications have been
demonstrated to induce potent CD4 cytotoxic T cells to eliminate
cancer. The Directors believe that this platform has the potential
to eradicate hard to treat solid tumours.
AvidiMab(TM) has broad potential to increase the avidity or
potency of any therapeutic monoclonal antibody (mAb) including
those being developed for autoimmune diseases, as well as cancer.
Scancell's development pipeline includes mAbs against specific
tumour-associated glycans (TaGs) with superior affinity and
selectivity profiles, that have now been further engineered using
the Company's AvidiMab(TM) technology; this confers the Scancell
anti-TaG mAbs with the ability to directly kill tumour cells. The
mAbs targeting TaGs can also be used to deliver cytotoxic payload
to cancer or to redirect T cells. The Company has entered into
three non-exclusive research agreements with leading antibody
technology companies to evaluate the Company's anti-TaG mAbs
including those enhanced with the AvidiMab(TM) technology.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBSBDGIXBDGBS
(END) Dow Jones Newswires
October 15, 2021 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Scancell (LSE:SCLP)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024